The CSCO 2022 gastric cancer guideline adopts dMMR/MSI-H as a routine test for all patients with newly diagnosed gastric cancer regardless of HER-2 status and, moreover, offers new treatment recommendations for the dMMR/MSI-H population. Here, ERBB2 is linked to gastric cancer.